IP Library › Granted Patent US 12,226,480
Granted Patent B2
US 12,226,480 · App. 16/772,846 · Granted Feb 18, 2025

Combination drug including TLR7 agonist

Inventors: Yosuke Ota (Osaka, JP); Takeshi Otsubo (Toyonaka, JP)
Assignee: SUMITOMO PHARMA CO., LTD.
A61K39/3955A61K31/437A61K31/505A61K31/522A61P35/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,226,480
App. No.
16/772,846
Granted
Feb 18, 2025
Kind
B2
Abstract

The present invention provides an agent for inducing effector memory T cell or an agent for inducing MHC class I for treating or preventing a cancer, comprising a TLR7 agonist which is used with an immune checkpoint inhibitor. And, the present invention also provides a medicament for treating or preventing a cancer, comprising a TLR7 agonist which is used with an immune checkpoint inhibitor.

Claims (48)

1. A method for inducing an effector memory T cell response or inducing an MHC class I response in a human patient in need thereof, comprising

administering to the human patient a therapeutically effective amount of a TLR7 agonist in combination with a therapeutically effective amount of an immune checkpoint inhibitor,

wherein the TLR7 agonist is N-{4-[(2-amino-4-{[(3S)-1-hydroxyhexan-3-yl]amino}-6-methylpyrimidin-5-yl)methyl]-3-methoxybenzyl}-N-(2,2,2-trifluoroethyl)glycine, N-{4-[(2-amino-4-{[(3S)-1-hydroxyhexan-3-yl]amino}-6-methylpyrimidin-5-yl)methyl]-3-methoxybenzyl}-N-(2,2-difluoroethyl)glycine, or a pharmaceutically acceptable salt thereof, and

the immune checkpoint inhibitor is an anti-PD-1 antibody, or an anti-CTLA-4 antibody, and

wherein the TLR7 agonist is administered prior or posterior to the immune checkpoint inhibitor, and

wherein the human patient has a cancer and is refractory to the immune checkpoint inhibitor.

2. The method according to claim 1 , wherein the cancer is selected from the group consisting of non-small-cell lung cancer, small cell lung cancer, pancreatic cancer, malignant melanoma, renal cell carcinoma, gastric cancer, colon cancer, rectal cancer, small intestinal cancer, breast cancer, germ cell cancer, bladder cancer, prostate cancer, endometrial cancer, cervical cancer, ovarian cancer, liver cancer, Merkel cell carcinoma, bone cancer, head and neck cancer, cutaneous malignant melanoma, intraorbital malignant melanoma, anal cancer, testicular cancer, esophageal cancer, endocrine system cancer, thyroid cancer, parathyroid cancer, adrenal cancer, soft tissue sarcoma, urothelial cancer, penile cancer, glioblastoma multiforme, brain tumor, chronic leukemia, acute leukemia, malignant lymphoma, myelodysplastic syndrome, and multiple myeloma.

3. The method according to claim 2 , wherein the cancer is acute myeloid leukemia, chronic myeloid leukemia, acute lymphoblastic leukemia, chronic lymphocytic leukemia, Hodgkin's lymphoma, or non-Hodgkin's lymphoma.

4. The method according to claim 1 , wherein the human patient has relapsed with the cancer.

5. The method according to claim 1 , which effects a long-term anticancer immunity.

6. The method according to claim 1 , wherein the TLR7 agonist is N-{4-[(2-amino-4-{[(3S)-1-hydroxyhexan-3-yl]amino}-6-methylpyrimidin-5-yl)methyl]-3-methoxybenzyl}-N-(2,2,2-trifluoroethyl)glycine, or a pharmaceutically acceptable salt thereof.

7. The method according to claim 1 , wherein the immune checkpoint inhibitor is pembrolizumab.

8. The method according to claim 1 , wherein the immune checkpoint inhibitor is an anti-PD-1 antibody.

9. The method according to claim 1 , wherein the immune checkpoint inhibitor is an anti-CTLA-4 antibody.

10. The method according to claim 1 , wherein the anti-PD-1 antibody is nivolumab, pembrolizumab, cemiplimab, tislelizumab, dostarlimab, spartalizumab, camrelizumab, sintilimab, BI-754091, ABBV-181, CC-90006, AGEN-2034w, LZM-009, Sym-021, HLX-10, or BCD-100,

the anti-CTLA-4 antibody is ipilimumab, tremelimumab, BMS-986218, MK-1308, or BMS-986249.

11. The method according to claim 1 , wherein the TLR7 agonist and the immune checkpoint inhibitor are simultaneously administered.

12. The method according to claim 1 , wherein the TLR7 agonist and the immune checkpoint inhibitor are separately administered.

13. The method according to claim 1 , wherein the TLR7 agonist is administered prior to the immune checkpoint inhibitor.

14. The method according to claim 1 , wherein the TLR7 agonist is administered posterior to the immune checkpoint inhibitor.

15. The method according to claim 1 , wherein the method induces an effector memory T cell response in the human patient in need thereof.

16. The method according to claim 1 , wherein the method induces an MHC class I response in the human patient in need thereof.

17. A method for treating a cancer in a human patient in need thereof, comprising

administering to the human patient a therapeutically effective amount of a TLR7 agonist selected from N-{4-[(2-amino-4-{[(3S)-1-hydroxyhexan-3-yl]amino}-6-methylpyrimidin-5-yl)methyl]-3-methoxybenzyl}-N-(2,2,2-trifluoroethyl)glycine, N-{4-[(2-amino-4-{[(3S)-1-hydroxyhexan-3-yl]amino}-6-methylpyrimidin-5-yl)methyl]-3-methoxybenzyl}-N-(2,2-difluoroethyl)glycine, or a pharmaceutically acceptable salt thereof,

in combination with a therapeutically effective amount of an immune checkpoint inhibitor, wherein the immune checkpoint inhibitor is an anti-PD-1 antibody or an anti-CTLA-4 antibody, and

wherein the human patient is refractory to the immune checkpoint inhibitor.

18. The method according to claim 17 , wherein the TLR7 agonist is N-{4-[(2-amino-4-{[(3S)-1-hydroxyhexan-3-yl]amino}-6-methylpyrimidin-5-yl)methyl]-3-methoxybenzyl}-N-(2,2,2-trifluoroethyl)glycine, or a pharmaceutically acceptable salt thereof.

19. The method according to claim 17 , wherein the immune checkpoint inhibitor is pembrolizumab.

20. The method according to claim 17 , wherein the immune checkpoint inhibitor is an anti-PD-1 antibody.

21. The method according to claim 17 , wherein the immune checkpoint inhibitor is an anti-CTLA-4 antibody.

22. The method according to claim 17 , wherein the anti-PD-1 antibody is nivolumab, pembrolizumab, cemiplimab, tislelizumab, dostarlimab, spartalizumab, camrelizumab, sintilimab, BI-754091, ABBV-181, CC-90006, AGEN-2034w, LZM-009, Sym-021, HLX-10, or BCD-100,

the anti-CTLA-4 antibody is ipilimumab, tremelimumab, BMS-986218, MK-1308, or BMS-986249.

23. The method according to claim 17 , wherein the human patient suffers from relapse of the cancer.

24. The method according to claim 17 , wherein the method effects a long-term anticancer immunity.

25. A method for treating a cancer in a human patient in need thereof, which comprises administering to the human patient a therapeutically effective amount of N-{4-[(2-amino-4-{[(3S)-1-hydroxyhexan-3-yl]amino}-6-methylpyrimidin-5-yl)methyl]-3-methoxybenzyl}-N-(2,2,2-trifluoroethyl)glycine, N-{4-[(2-amino-4-{[(3S)-1-hydroxyhexan-3-yl]amino}-6-methylpyrimidin-5-yl)methyl]-3-methoxybenzyl}-N-(2,2-difluoroethyl)glycine, or a pharmaceutically acceptable salt thereof, and a therapeutically effective amount of an immune checkpoint inhibitor, wherein the immune checkpoint inhibitor is an anti-PD-1 antibody or an anti-CTLA-4 antibody, and

wherein the human patient is refractory to the immune checkpoint inhibitor.

26. The method according to claim 1 , wherein the cancer is chosen from head and neck cancer, renal cell carcinoma, Hodgkin's lymphoma, non-small-cell lung cancer, and gastric cancer.

27. The method of according to claim 17 , wherein the cancer is chosen from non-small-cell lung cancer; small cell lung cancer; pancreatic cancer; malignant melanoma; renal cell carcinoma; gastric cancer; colon cancer; rectal cancer; small intestinal cancer; breast cancer; germ cell cancer; bladder cancer; prostate cancer; endometrial cancer; cervical cancer; ovarian cancer; liver cancer; Merkel cell carcinoma; bone cancer; head and neck cancer; cutaneous or intraorbital malignant melanoma; anal cancer; testicular cancer; esophageal cancer; endocrine system cancer; thyroid cancer; parathyroid cancer; adrenal cancer; soft tissue sarcoma; urothelial cancer; penile cancer; glioblastoma multiforme; brain tumor; chronic or acute leukemia; malignant lymphoma; myelodysplastic syndrome; and multiple myeloma.

28. The method according to claim 27 , wherein the chronic or acute leukemia is acute myeloid leukemia, chronic myeloid leukemia, acute lymphoblastic leukemia, or chronic lymphocytic leukemia, and wherein the malignant lymphoma is Hodgkin's lymphoma or non-Hodgkin's lymphoma.

29. The method according to claim 17 , wherein the cancer is chosen from head and neck cancer, renal cell carcinoma, Hodgkin's lymphoma, non-small-cell lung cancer, and gastric cancer.

30. The method of according to claim 25 , wherein the cancer is chosen from non-small-cell lung cancer; small cell lung cancer; pancreatic cancer; malignant melanoma; renal cell carcinoma; gastric cancer; colon cancer; rectal cancer; small intestinal cancer; breast cancer; germ cell cancer; bladder cancer; prostate cancer; endometrial cancer; cervical cancer; ovarian cancer; liver cancer; Merkel cell carcinoma; bone cancer; head and neck cancer; cutaneous or intraorbital malignant melanoma; anal cancer; testicular cancer; esophageal cancer; endocrine system cancer; thyroid cancer; parathyroid cancer; adrenal cancer; soft tissue sarcoma; urothelial cancer; penile cancer; glioblastoma multiforme; brain tumor; chronic or acute leukemia malignant lymphoma; myelodysplastic syndrome; and multiple myeloma.

31. The method according to claim 30 , wherein the chronic or acute leukemia is acute myeloid leukemia, chronic myeloid leukemia, acute lymphoblastic leukemia, or chronic lymphocytic leukemia, and wherein the malignant lymphoma is Hodgkin's lymphoma or non-Hodgkin's lymphoma.

32. The method according to claim 25 , wherein the cancer is chosen from head and neck cancer, renal cell carcinoma, Hodgkin's lymphoma, non-small-cell lung cancer, and gastric cancer.

33. A method for inducing an effector memory T cell response or inducing an MHC class I response in a human patient in need thereof, comprising:

administering to the human patient a therapeutically effective amount of TLR7 agonist sufficient for TLR7 activation to produce cytokine induction and enhancement of antigen presentation in the mammal, wherein the TLR7 agonist is chosen from N-{4-[(2-amino-4-{[(3S)-1-hydroxyhexan-3-yl]amino}-6-methylpyrimidin-5-yl)methyl]-3-methoxybenzyl}-N-(2,2,2-trifluoroethyl)glycine, N-{4-[(2-amino-4-{[(3S)-1-hydroxyhexan-3-yl]amino}-6-methylpyrimidin-5-yl)methyl]-3-methoxybenzyl}-N-(2,2-difluoroethyl)glycine, or a pharmaceutically acceptable salt thereof; and

administering to the human patient a therapeutically effective amount of an immune checkpoint inhibitor sufficient to inhibit immune checkpoint molecules that suppress the function of effector T cells in the human patient, wherein the immune checkpoint inhibitor is chosen from an anti-PD-1 antibody or an anti-CTLA-4 antibody;

wherein the TLR7 agonist and the checkpoint inhibitor are in a weight ratio effective to increase the amount of effector memory T cells or the amount of MHC class I molecules greater than the sum of any increase in amount of effector memory T cells or the amount of MHC class I molecules produced by the TLR7 agonist alone and the checkpoint inhibitor alone in the mammal, and

wherein the human patient has a cancer and is refractory to the immune checkpoint inhibitor.

Assignments (2)
CHANGE OF NAME Recorded Jun 21, 2022
From: SUMITOMO DAINIPPON PHARMA CO., LTD.
To: SUMITOMO PHARMA CO., LTD.
Reel/Frame 060455/0269 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 24, 2020
From: OTA, YOSUKE; OTSUBO, TAKESHI
To: SUMITOMO DAINIPPON PHARMA CO., LTD.
Reel/Frame 053020/0862 →
Priority Claims (1)
JP 2017-244675 · Dec 21, 2017 · national
Continuity (1)
Related Publication 20210170022A1 · Jun 10, 2021
References Cited (50)
US 20100093998A1 · Isobe et al. · 2010 [cited by applicant]
US 20110077263A1 · Kast et al. · 2011 [cited by applicant]
US 20140341978A1 · Kim et al. · 2014 [cited by applicant]
US 20150099770A1 · Hori et al. · 2015 [cited by applicant]
US 20170114137A1 · Li · 2017 [cited by applicant]
US 20170216276A1 · Vasilakos et al. · 2017 [cited by applicant]
US 20180127717A1 · Decker et al. · 2018 [cited by applicant]
US 20180311505A1 · Fisher et al. · 2018 [cited by applicant]
JP 2015520729A · 2015 [cited by applicant]
JP 2017523244A · 2017 [cited by applicant]
WO WO2008114817A1 · 2008 [cited by applicant]
WO WO2013043647A1 · 2013 [cited by applicant]
WO WO2013172479A1 · 2013 [cited by applicant]
WO WO2016019232A1 · 2016 [cited by applicant]
WO WO2016179475A1 · 2016 [cited by applicant]
WO WO2017079431A1 · 2017 [cited by applicant]
WO WO2018078620A1 · 2018 [cited by applicant]
Marin-Acevedo et al (Journal of Hematology and Oncology, 2018, vol. 11, 20 pages) (Year: 2018). [cited by examiner]
Yuan et al (Cancer Immunol Immunother, 2011, vol. 60, pp. 1137-1146) (Year: 2011). [cited by examiner]
Fujimura et al (Case Reports in Oncology, Jan. 4, 2018, vol. 11, pp. 1-5) (Year: 2019). [cited by examiner]
Pardoll, Nature Reviews Cancer, 2012, vol. 12, pp. 252-264 (Year: 2012). [cited by examiner]
Extended European Search Report from the European Patent Office in European Application No. EP 18 89 3082, dated Dec. 9, 2021 (24 pages). [cited by applicant]
Mahoney, Kathleen M., et al., “Combination cancer immunotherapy and new immunomodulatory targets”, [cited by applicant]
Pardoll, Drew M., “The blockade of immune checkpoints in cancer immunotherapy”, [cited by applicant]
Mahoney, Kathleen M., et al., “Combination cancer immunotherapy and new immunomodulatory targets”, [cited by applicant]
Singh, Manisha et al., “Effective Innate and Adaptive Antimelanoma Immunity through Localized TLR7/8 Activation”, [cited by applicant]
Rausch, Johanna et al., “Combined immunotherapy: CTLA-4 blockage potentiates anti-tumor response induced by transcutaneous immunization”, [cited by applicant]
Nishii, Naoto et al., “Systemic administration of a TLR7 agonist attenuates regulatory T cells by dendritic cell modification and overcomes resistance to PD-L1 blockade therapy”, [cited by applicant]
International Search Report in corresponding International Application No. PCT/JP2018/047011, mailed Mar. 19, 2019 (3 pages). [cited by applicant]
International Preliminary Report on Patentability in corresponding International Application No. PCT/JP2018/047011, issued Jun. 23, 2020 (12 pages). [cited by applicant]
Dyck, Lydia et al., “Anti-PD-1 inhibits Foxp3+ Treg cell conversion and unleashes intratumoural effector T cells thereby enhancing the efficacy of a cancer vaccine in a mouse model”, [cited by applicant]
Joseph, Richard W. et al., “Treatment of in-transit and metastatic melanoma in two patients treated with ipilimumab and topical imiquimod”, [cited by applicant]
Naoto Nishii et al., “Combined Treatment With PD-L1 Blockade and a TLR7/8 Agonist Dramaticallly Enhances Antitumor Immunity”, [cited by applicant]
Fumi Sato-Kaneko et al., “Immunotherapy of head and neck squamous cell cancers with synthetic TLR agonists and checkpoint inhibitors in preclinical models”, [cited by applicant]
Xu, Jun et al., “Near-Infrared-Triggered Photodynamic Therapy with Multitasking Upconversion Nanoparticles in Combination with Checkpoint Blockade for Immunotherapy of Colorectal Cancer”, [cited by applicant]
Chen, Qian et al., “Photothermal therapy with immune-adjuvant nanoparticles together with checkpoint blockade for effective cancer immunotherapy”, [cited by applicant]
Carson, Dennis et al.: “Application of novel phospholipid conjugated Toll like receptor 7 ligands for cancer therapy by topical and systemic administration”, [cited by applicant]
[cited by applicant]
Nishii, Naoto et al., “Antitumor effects of a low dose systemic administration of a TLR7/8 agonist and its combined therapy with PD-L1 blockade”, Annual Meeting of the Japanese Society for Immunology (JSI) 2016, p. 136 … [cited by applicant]
Popivanova, Boryana K. et al., “Anti-tumor activity of TLR7 stimulation through enhanced anti-tumor CTL induction,” Annual Meeting of the Japanese Society for Immunology (JSI) 2012, p. 173 (1 page). [cited by applicant]
Supplement slides used in Annual Meeting of the Japanese Society for Immunology (JSI) 2012, p. 173 (17 pages). [cited by applicant]
Supplementary Partial European Search Report from the European Patent Office dated Aug. 13, 2021, in European Application No. EP 18893082, 23 pages. [cited by applicant]
Fumi Sato-Kaneko et al., “Combination immunotherapy with TLR agonists and checkpoint inhibitors suppresses head and neck cancer”, JCI Insight, vol. 2, No. 18, Sep. 21, 2017, pp. 1-18. [cited by applicant]
Andrea Khong et al., “The efficacy of tumor debulking surgery is improved by adjuvant immunotherapy using imiquimod and anti-CD40”, BMC Cancer, Biomed Central, London, vol. 14, No. 1, Dec. 17, 2014, pp. 1-9. [cited by applicant]
Steve A. Bloomfield et al., “Locally Administered TLR7 Agonists Drive Systemic Antitumor Immune Responses That Are Enhanced by Anti-CD40 Immunotherapy”, The Journal of Immunology, Williams & Wilkins Co., US, vol. 182, N… [cited by applicant]
Anonymous: “CD40 & DC40L Immune Checkpoint Pathway : Sino Biological”, Jan. 1, 2021, Retrieved from the Internet: https://www.sinobiological.com/research/immune-checkpoint/cd40-cd40l-pathway [retrieved on Aug. 9, 2021],… [cited by applicant]
Kharkeyvich, D. A., “Pharmacology,” Manual for High Schools, Tenth Edition, GEOTAR-Media, Moscow, Russia, (2010), 27 pages. [cited by applicant]
Mashkovsky, M. D., “Drugs,” Manual for Physicians, vol. 1, Fourteenth Edition, Novaya Volna: S.B. Divov, Moscow, Russia, (2001), 7 pages. [cited by applicant]
Tallarida, R. J. et al., “Quantitative Methods for Assessing Drug Synergism,” Genes & Cancer, vol. 2, No. 11, (2011), pp. 1003-1008. [cited by applicant]
Vengerovsky, A. I., “Pharmacological incompatibility,” Bulletin of Siberian Medicine, Siberian State Medical University—Tomsk, Russia, (2003), 18 pages. [cited by applicant]